Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Association of baseline systemic corticosteroid use with overall survival and time to next treatment in patients receiving immune checkpoint inhibitor therapy in real-world US oncology practice for advanced non-small cell lung cancer, melanoma, or urothelial carcinoma ONCOIMMUNOLOGY Drakaki, A., Dhillon, P. K., Wakelee, H., Chui, S. Y., Shim, J., Kent, M., Degaonkar, V., Hoang, T., McNally, V., Luhn, P., Gutzmer, R. 2020; 9 (1)
View details for DOI 10.1080/2162402X.2020.1824645
View details for Web of Science ID 000576987400001